Nervalin CR 82.5 mg Capsule contains Pregabalin in a controlled-release (CR) formulation, designed to provide sustained and consistent therapeutic levels over a 24-hour period. This once-daily formulation improves patient compliance while effectively managing neuropathic pain and seizure disorders. Nervalin CR 82.5 mg is particularly useful during dose conversion from immediate-release Pregabalin or in patients requiring stable plasma concentrations with reduced dosing frequency.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Supplemental antiepileptic medications

Indications

Nervalin CR 82.5 mg is indicated for the treatment of the following conditions:

• Neuropathic pain associated with diabetic peripheral neuropathy (DPN)

• Post-herpetic neuralgia (PHN) following shingles

• Adjunctive therapy for partial-onset seizures in patients older than one month

• Fibromyalgia

• Neuropathic pain associated with spinal cord injury

The controlled-release formulation is specifically approved for:

• Neuropathic pain due to diabetic peripheral neuropathy

• Post-herpetic neuralgia

Pharmacology

Pregabalin, the active ingredient in Nervalin CR 82.5 mg, is a structural analogue of gamma-aminobutyric acid (GABA). It does not bind directly to GABAA, GABAB, or benzodiazepine receptors. Instead, Pregabalin binds with high affinity to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. This binding reduces calcium influx into presynaptic neurons and suppresses the release of excitatory neurotransmitters involved in pain perception and seizure propagation. Nervalin CR 82.5 mg demonstrates approximately 90% oral bioavailability, independent of dose, and is excreted largely unchanged through the kidneys. The mean elimination half-life is about 6.3 hours in patients with normal renal function.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Dosage and Administration

Dosage should be individualized based on indication, response, and renal function.

• Diabetic Peripheral Neuropathy: Initiate CR therapy at 165 mg once daily and increase to 330 mg once daily within one week if required.

• Post-Herpetic Neuralgia: Start with 165 mg once daily and titrate up to 330 mg once daily. In selected patients, doses up to 660 mg once daily may be used.

• Fibromyalgia: Equivalent daily doses of 300–450 mg may be used based on clinical response.

• Partial-Onset Seizures and Spinal Cord Injury-Related Neuropathic Pain: Total daily dose ranges from 150–600 mg, adjusted gradually.

Nervalin CR 82.5 mg should be taken orally once daily after the evening meal. The capsule must be swallowed whole and should not be crushed, chewed, or divided.

Contraindications

Nervalin CR 82.5 mg is contraindicated in patients with known hypersensitivity to Pregabalin or any of the formulation components.

Side Effects

Common adverse effects include dizziness, somnolence, dry mouth, peripheral edema, blurred vision, weight gain, and difficulty with concentration or attention. Increased appetite and weight gain may occur, particularly in pediatric patients receiving therapy for seizures.

Pregnancy and Lactation

Nervalin CR 82.5 mg is classified as Pregnancy Category C. It should be used during pregnancy only if the expected benefit outweighs potential fetal risks. Pregabalin is excreted in breast milk; therefore, breastfeeding is not recommended unless clearly necessary.

Precautions and Warnings

Patients should be monitored for angioedema, hypersensitivity reactions, suicidal thoughts, respiratory depression when used with CNS depressants, and dizziness that may impair driving or operating machinery. Discontinuation should be gradual over at least two weeks to avoid withdrawal symptoms or seizure exacerbation.

Storage Conditions

Store below 30°C in a cool, dry place, protected from light and moisture. Keep out of reach of children.